Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus PROVENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus PROVENTIL.
ISOETHARINE HYDROCHLORIDE vs PROVENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
Inhalation: 2 inhalations (90 mcg each) every 4-6 hours as needed; oral: 2-4 mg three to four times daily; extended-release: 4-8 mg every 12 hours.
None Documented
None Documented
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life: 3.8–6 hours (inhalation), 3.7–7.1 hours (oral); clinical context: supports dosing every 4–6 hours as needed.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Renal: ~90% (mostly as sulfate conjugates after oral administration, unchanged drug after inhalation); biliary/fecal: <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist